Product Description
XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00491699)
Mechanisms of Action: SSK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Symphony Evolution
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ovarian Cancer|Multiple Myeloma|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Colorectal Cancer|Renal Cell Carcinoma
Phase 1: Non-Small-Cell Lung Cancer|Oncology Unspecified|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTRC 10-08 | N/A |
No longer available |
Oncology Unspecified |
2012-06-01 |
|
| XL999-900 | P1 |
Completed |
Oncology Unspecified |
2010-05-01 |
|
| XL999-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2008-09-01 |
|
| XL999-002 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-01-01 |